within Pharmacolibrary.Drugs.ATC.L;

model L01EX08
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.85,
    Cl             = 0.11666666666666667,
    adminDuration  = 600,
    adminMass      = 0.024,
    adminCount     = 1,
    Vd             = 0.1,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.007116666666666666,
    Tlag           = 10.020000000000001
  );

  annotation(Documentation(
    info ="<html><body><p>Lenvatinib is a multi-kinase inhibitor indicated for the treatment of certain types of cancer, including differentiated thyroid cancer, renal cell carcinoma, and hepatocellular carcinoma. It is an oral anticancer drug currently approved for use in several regions including the US and EU.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetic analysis in patients with advanced solid tumors, administered orally, typical adult population.</p><h4>References</h4><ol><li><p>Wei, Y, et al., &amp; Zhang, X (2023). Effects of diet and gender on the pharmacokinetics of oral lenvatinib: A clinical trial in healthy Chinese participants. <i>International journal of clinical pharmacology and therapeutics</i> 61(11) 475–481. DOI:<a href=&quot;https://doi.org/10.5414/CP204440&quot;>10.5414/CP204440</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37644876/&quot;>https://pubmed.ncbi.nlm.nih.gov/37644876</a></p></li><li><p>Shumaker, R, et al., &amp; Ren, M (2015). Influence of hepatic impairment on lenvatinib pharmacokinetics following single-dose oral administration. <i>Journal of clinical pharmacology</i> 55(3) 317–327. DOI:<a href=&quot;https://doi.org/10.1002/jcph.398&quot;>10.1002/jcph.398</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25204557/&quot;>https://pubmed.ncbi.nlm.nih.gov/25204557</a></p></li><li><p>Mizuo, H, &amp; Mano, Y (2023). Cross-species comparison in nonclinical pharmacokinetics of lenvatinib by a simple HPLC with ultraviolet detection. <i>Scientific reports</i> 13(1) 8349–None. DOI:<a href=&quot;https://doi.org/10.1038/s41598-023-35297-z&quot;>10.1038/s41598-023-35297-z</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/37221226/&quot;>https://pubmed.ncbi.nlm.nih.gov/37221226</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01EX08;
